Expert Opinion on Pharmacotherapy最新文献_第5页

Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis. 40 岁及以上女性服用抗抑郁药物与脆性骨折风险：系统文献综述和荟萃分析。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-03 DOI: 10.1080/14656566.2024.2409316

Dana Alsugeir, Merit John, Emma Tillyer, Li Wei, Ruth Brauer

{"title":"Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis.","authors":"Dana Alsugeir, Merit John, Emma Tillyer, Li Wei, Ruth Brauer","doi":"10.1080/14656566.2024.2409316","DOIUrl":"10.1080/14656566.2024.2409316","url":null,"abstract":"Introduction: Antidepressants and menopause are risk factors which are independently associated with an increased risk of fractures. This review aims to investigate the risk of fragility fractures in women aged 40 and older and prescribed antidepressants.Methods: A literature search was conducted using PubMed, Ovid Embase, Ovid PsychINFO, Web of Science, and Scopus from inception to 1 June 2024. Relevant citations were identified and screened against our inclusion/exclusion criteria. The study population comprised women over 40 years. The risk of fragility fractures was compared between users and non-users of antidepressants. Risk of bias assessment was carried out using the ROBINS-I tool. A meta-analysis of cohort studies was performed to assess fracture risk associated with prescribing of any antidepressant agents, and SSRIs specifically.Results: Of the 3,676 articles retrieved, five observational studies were found eligible for inclusion (n = 1,240,354). In a meta-analysis of 4 studies, an increased risk of fractures in women was associated with the prescribing of antidepressants (HR = 1.62, 95% CI: 1.15-2.28; I2 = 96.50%) and SSRIs in particular (HR = 1.36, 95% CI: 1.20-1.55; I2 = 40.32%).Conclusions: Findings from this review suggest that prescribing of antidepressants is associated with an increased risk of fractures in women aged 40 and older. Substantial heterogeneity between studies may have affected the results of the meta-analysis.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1961-1970"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New antibiofilm strategies for the management of nontuberculous mycobacteria diseases. 治疗非结核分枝杆菌疾病的抗生物膜新策略。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-09 DOI: 10.1080/14656566.2024.2412250

María Cano-Fernández, Jaime Esteban

{"title":"New antibiofilm strategies for the management of nontuberculous mycobacteria diseases.","authors":"María Cano-Fernández, Jaime Esteban","doi":"10.1080/14656566.2024.2412250","DOIUrl":"10.1080/14656566.2024.2412250","url":null,"abstract":"Introduction: Nontuberculous mycobacteria (NTM) represent a group of microorganisms comprising more than 190 species. NTM infections have increased recently, and their treatment is a major challenge because to their resistance to conventional treatments. This review focuses on innovative strategies aimed at eradicating NTM biofilms, a critical factor in their resistance. Important areas addressed include biofilm formation mechanisms, current therapeutic challenges, and novel treatment approaches. The main objective is to compile and analyze information on these emerging strategies, identifying pivotal research directions and recent advancements.Areas covered: A review of the scientific literature was conducted to identify emerging novel therapies for the treatment of NTM infections and to explore potential synergies with existing treatments.Expert opinion: Experts highlights a limited understanding of optimal treatment regimens, often supported by insufficient scientific evidence. Current therapies are typically prolonged, involve multiple antibiotics with adverse effects, and frequently do not achieve patient cure. Certain species are even considered virtually impossible to eradicate. A thorough understanding of these new approaches is imperative for improving patients outcomes. This review provides a robust foundation for developing of more effective antibacterial strategies, which are essential because of the increasing incidence of NTM infections and the limitations of existing therapies.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2035-2046"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune-mediating and immunosuppressive pharmacotherapies for proliferative lupus nephritis. 增殖性狼疮肾炎的免疫介导和免疫抑制药物疗法。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-14 DOI: 10.1080/14656566.2024.2416038

Gabriella Moroni, Francesco Reggiani, Claudio Ponticelli

{"title":"Immune-mediating and immunosuppressive pharmacotherapies for proliferative lupus nephritis.","authors":"Gabriella Moroni, Francesco Reggiani, Claudio Ponticelli","doi":"10.1080/14656566.2024.2416038","DOIUrl":"10.1080/14656566.2024.2416038","url":null,"abstract":"Introduction: Proliferative lupus nephritis is a common and severe complication of systemic lupus erythematosus. Affected patients are at an increased risk of developing chronic kidney disease, end-stage kidney disease, and extra-renal comorbidities. In recent years, the prognosis for patients with proliferative lupus nephritis has improved thanks to advancements in management regimens. Despite these advances, lupus nephritis continues to present therapeutic complexities and unmet needs.Areas covered: Research was conducted across major databases to identify the most relevant articles pertaining to immune-mediating and immunosuppressive therapies in lupus nephritis.Expert opinion: The prognosis for patients with proliferative lupus nephritis remains severe. Some drugs used in this disease may be unable to control activity, and most of them have a low therapeutic index and may cause severe and life-threatening side effects. Nonetheless, better management of traditional drugs and the introduction of novel therapies have improved renal prognosis and reduced local and systemic adverse events in patients with proliferative lupus nephritis.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2061-2076"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome. 关于钠-葡萄糖共转运体-2 抑制剂对多囊卵巢综合征患者代谢和内分泌特征影响的系统综述。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-09-24 DOI: 10.1080/14656566.2024.2407513

Madhura Roy, Rizwana Parveen, Parvej Khan, Haya Majid, Mani Pathak, Rajesh Saxena, Nidhi

{"title":"A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome.","authors":"Madhura Roy, Rizwana Parveen, Parvej Khan, Haya Majid, Mani Pathak, Rajesh Saxena, Nidhi","doi":"10.1080/14656566.2024.2407513","DOIUrl":"10.1080/14656566.2024.2407513","url":null,"abstract":"Background: Polycystic ovarian syndrome (PCOS) has been a common metabolic and endocrinal disorder, prevalent amongst women belonging to the reproductive age group. The aim of this systematic review was to assess the safety and efficacy profile of sodium-glucose cotransporter 2 (SGLT2) inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, and Licogliflozin) for the treatment of women suffering from PCOS.Methods: A literature search in PubMed, Science Direct, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov was conducted for randomized clinical trials of SGLT-2 inhibitors in PCOS patients by applying predetermined inclusion and exclusion criteria. The articles in English language were included.Results: Four randomized controlled trials including 146 subjects were included in the review. The clinical studies indicated a significant decrease in the levels of total testosterone, free androgen index, total body fat, homeostasis model assessment-estimated insulin resistance (HOMA-IR), body mass index (BMI), dehydroepiandrosterone sulfate (DHEAS) and fasting plasma glucose (FPG). However, no significant difference was reported in levels of sex hormone-binding globulin (SHBG). Overall, there was improvement in metabolic and endocrine profiles, suggesting a potentially beneficial impact of SGLT2 inhibitors in the management of PCOS.Conclusion: There is a requirement for large extensive clinical trials to demonstrate the efficacy of SGLT-2 inhibitors in PCOS patients.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1953-1960"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aztreonam-avibactam for the treatment of intra-abdominal infections. 用于治疗腹腔内感染的阿曲霉素-阿维巴坦。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-07 DOI: 10.1080/14656566.2024.2409950

Hannah Delp, Gabrielle A Gibson, Sara A Buckman

{"title":"Aztreonam-avibactam for the treatment of intra-abdominal infections.","authors":"Hannah Delp, Gabrielle A Gibson, Sara A Buckman","doi":"10.1080/14656566.2024.2409950","DOIUrl":"10.1080/14656566.2024.2409950","url":null,"abstract":"Introduction: Intra-abdominal infections are becoming increasingly common and can lead to significant morbidity and mortality. The incidence of these infections due to resistant gram-negative organisms is also increasing. Given this resistance, new antibiotic combinations are being developed, often utilizing older antibiotics and newer β-lactamase inhibitors. Aztreonam/avibactam (ATM-AVI) is one of the combination antibiotics, which combines aztreonam, a monobactam, with avibactam, a broad-spectrum β-lactamase inhibitor for the treatment of complicated intra-abdominal infections in combination with metronidazole.Areas covered: In this drug evaluation manuscript, we provide an overview of intra-abdominal infections and an overview of currently available antimicrobial agents used to treat these infections. ATM-AVI is introduced, including chemistry, pharmacodynamics, pharmacokinetics and clinical studies of this compound.Expert opinion: There are limited treatment options for complicated intra-abdominal infections due to resistant gram-negative organisms, especially those with metallo-β-lactamases. One treatment option for these infections is ATM-AVI, which was recently approved in Europe, in addition to metronidazole. These bacteria are difficult to treat, and this new compound is a safe and effective option for empiric treatment in places with a high incidence of infections due to these bacteria, and also treatment for infections when these resistant bacteria are isolated in culture.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1867-1872"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance. 非索内酯：一种治疗更年期血管运动症状的新型非激素疗法，需要仔细评估其效益与风险的平衡。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-09-29 DOI: 10.1080/14656566.2024.2410398

Jonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné

引用次数: 0

Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer? 将 obicetrapib 作为血脂异常患者的新兴治疗方法进行评估：游戏规则的改变者？

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-09-27 DOI: 10.1080/14656566.2024.2409324

Stephen J Nicholls, Sean Tan, Julie Butters, Adam J Nelson

{"title":"Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?","authors":"Stephen J Nicholls, Sean Tan, Julie Butters, Adam J Nelson","doi":"10.1080/14656566.2024.2409324","DOIUrl":"10.1080/14656566.2024.2409324","url":null,"abstract":"Introduction: Cholesteryl ester transfer protein (CETP) plays an important role in lipid metabolism. Early interest in the development of CETP inhibitors proved to be disappointing. Recent interest has focused on the potential for CETP inhibition to reduce cardiovascular risk by lowering levels of low-density lipoprotein cholesterol (LDL-C).Areas covered: The data suggesting that low CETP activity may associate with lower levels of cardiovascular risk and early experience with CETP inhibitors focused on raising HDL-C levels. More recent data that suggests that any potential to reduce cardiovascular risk by inhibition of CETP is more likely to result from lowering levels of atherogenic lipid parameters. The development of obicetrapib, a potent CETP inhibitor, with robust lowering of apoB and LDL-C, will be summarized as a potential approach to the prevention of cardiovascular disease.Expert opinion: Obicetrapib is a potent CETP inhibitor, with a demonstrated ability to lower levels of apoB and LDL-C as monotherapy and in addition to high intensity statin therapy. The ultimate impact of obicetrapib on cardiovascular events will be evaluated by ongoing clinical trials.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1879-1885"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rise and fall of decongestants in treating nasal congestion related diseases. 减充血剂在治疗鼻塞相关疾病方面的兴衰。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-06 DOI: 10.1080/14656566.2024.2411009

Jiang Wang, Ze-Fan Mao, Lei Cheng

{"title":"Rise and fall of decongestants in treating nasal congestion related diseases.","authors":"Jiang Wang, Ze-Fan Mao, Lei Cheng","doi":"10.1080/14656566.2024.2411009","DOIUrl":"10.1080/14656566.2024.2411009","url":null,"abstract":"Introduction: Decongestants are commonly used drugs in clinical practice, and they can relieve nasal congestion caused by factors like influenza, rhinitis, and acute upper respiratory tract infection.Areas covered: In this article, we review the research outcomes about decongestants, which aim to provide beneficial information that can guide the clinical application of decongestants for clinicians.Expert opinion: Although the use of nasal decongestants is increasingly limited, caution rather than prohibition is now advocated. Scientific and accurate use of nasal decongestants can achieve satisfactory clinical effectiveness on nasal congestion, and it is not easy to produce adverse reactions. Patients with severe nasal congestion may use nasal decongestants solely or in combination with nasal corticosteroids or nasal antihistamines to exert a synergistic effect. The concentration, dose, frequency, and time of nasal decongestants determine whether drug-induced rhinitis will occur. Additionally, we recommend patients not to buy nasal sprays with unknown ingredients on the internet or in pharmacy, so as to avoid the risk of rhinitis medicamentosa. For patients with rhinitis medicamentosa, the use of nasal decongestants should be stopped immediately. However, more evidence is still needed to standardize the clinical use of nasal decongestants.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1943-1951"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024. 胃食管反流病的药物治疗：2024 年的技术水平。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-16 DOI: 10.1080/14656566.2024.2416585

Pierfrancesco Visaggi, Luisa Bertin, Andrea Pasta, Francesco Calabrese, Matteo Ghisa, Elisa Marabotto, Mentore Ribolsi, Vincenzo Savarino, Nicola de Bortoli, Edoardo Vincenzo Savarino

{"title":"Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024.","authors":"Pierfrancesco Visaggi, Luisa Bertin, Andrea Pasta, Francesco Calabrese, Matteo Ghisa, Elisa Marabotto, Mentore Ribolsi, Vincenzo Savarino, Nicola de Bortoli, Edoardo Vincenzo Savarino","doi":"10.1080/14656566.2024.2416585","DOIUrl":"10.1080/14656566.2024.2416585","url":null,"abstract":"Introduction: Gastroesophageal reflux disease (GERD) is a chronic disease of the esophagus characterized by the regurgitation of stomach contents into the esophagus, causing troublesome symptoms and/or complications. Among patients with GERD, around 30% of patients have visible mucosal damage, while 70% have normal esophageal mucosa. Accordingly, the optimal pharmacological treatment of GERD should address different disease manifestations, including symptoms, the mucosal damage when present, and possible chronic complications, including strictures, Barrett's esophagus, and esophageal adenocarcinoma.Areas covered: Available medical treatments for GERD include proton pump inhibitors (PPIs), potassium-competitive acid blockers (PCABs), histamine receptor antagonists (H2-RAs), prokinetics, and mucosal protectants, such as alginates, hyaluronic acid/chondroitin-sulfate, and poliprotect. Each compound has its own advantages and disadvantages, and knowledge of expected benefits and tips for their use is paramount for the success of treatment. In addition, the appropriateness of indications for initiating treatment is also crucial to achieve positive results when managing GERD patients.Expert opinion: PPIs, PCABs, H2-RAs, prokinetics, and mucosal protectants can all be used in patients with GERD, but careful assessment of patients' characteristics as well as advantages and disadvantages of each therapeutic compound is essential to ensure successful treatment of GERD.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2077-2088"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elucidating the mechanisms and efficacy of antimalarial drugs in systemic lupus erythematosus. 阐明系统性红斑狼疮中抗疟药物的机制和疗效。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-09 DOI: 10.1080/14656566.2024.2412252

Diana Paredes-Ruiz, Daniel Martin-Iglesias, Laura Amo, Guillermo Ruiz-Irastorza

{"title":"Elucidating the mechanisms and efficacy of antimalarial drugs in systemic lupus erythematosus.","authors":"Diana Paredes-Ruiz, Daniel Martin-Iglesias, Laura Amo, Guillermo Ruiz-Irastorza","doi":"10.1080/14656566.2024.2412252","DOIUrl":"10.1080/14656566.2024.2412252","url":null,"abstract":"Introduction: Antimalarials (AMs) are old drugs with a wide range of beneficial effects in systemic lupus erythematosus (SLE) beyond the control of activity. The most recent debate is focused on defining the optimal doses to assure the best benefit/risk ratio.Areas covered: We have reviewed the pharmacological basis underlying the various therapeutic effects of AMs and the beneficial and toxic effects of HCQ, also discussing the role of mepacrine not only as a substitute in cases of maculopathy, but also as a very effective therapy combined with HCQ. We searched PubMed and Embase for articles published in English at any time. We used the terms \"hydroxychloroquine\" or \"mepacrine\" or \"chloroquine\" or \"antimalarials\", \"pharmacokinetics\", \"efficacy\", \"remission\", \"toxicity\", \"adherence\". We reviewed original research articles, large observational studies, systematic reviews, and expert consensus statements. Additionally, studies were identified through the assessment of the reference lists of the evaluated manuscripts.Expert opinion: We advocate for the widespread use of HCQ at stable doses of 200 mg/d (≤4 mg/kg/d for most patients) and also for the early combination therapy with mepacrine to assure a good control of SLE activity, and also a durable and safe use of these essential drugs for the management of SLE.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2047-2060"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0